The global populating is aging, and approximately 29% of people with diabetes worldwide are aged 65 years and older, ...

CompanyOverview|NYSE:NVO] Despite a massively successful run as Chief Executive Officer (CEO) of pharma giant Novo Nordisk ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Health-care companies rose as investors bet on anti-obesity products. Omada Health shares jumped after the maker of digital products that help track diet and other diabetes factors made its ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

Novo Nordisk NVO has seen strong momentum in recent years, driven by the commercial success of its blockbuster semaglutide ...

Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include ...

Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular ...

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

The European Medicines Agency said an eye condition that might cause loss of vision is a very rare side effect of Novo Nordisk's blockbuster drugs Ozempic and Wegovy.

Novo Nordisk's (NVO) weight loss drug semaglutide (Ozempic, Wegovy, Rybelsus) is linked to a rare eye condition called NAION ...